Basel, 3 December 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that at its December meeting the Board of Directors of Roche Holding Ltd has approved first proposals to the Annual General Meeting (AGM) scheduled for 15 March 2022. Mr Paul Bulcke, who has been serving on the Board of Directors since 2011,... Read more
Roche subsidiary TIB Molbiol rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant, as they continue to offer new and accurate detection solutions Three new testing kits are among the first to specify the mutations of the recently discovered Omicron variant, and can help manage the evolving COVID-19 pandemic Use of... Read more
TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemic The acquisition enables Roche to further expand the portfolio of currently over 45 CE-IVD assays and more than 100 research use assays on Roche’s LightCycler PCR instruments TIB Molbiol will continue to focus on the research and development... Read more
All proposals of the Board of Directors approved Audited statutory interim financial statements (standalone financial statements) of the Company as of 31 October 2021 approved Share capital reduction by cancellation of 53,309,000 bearer shares with a nominal value of CHF 1 each approved Basel, 26 November 2021 – On 4 November 2021, Roche (SIX: RO,... Read more
Phase III POLARIX trial showed Polivy plus R-CHP was the first treatment in two decades to significantly improve outcomes in newly diagnosed diffuse large B-cell lymphoma (DLBCL) versus the standard of care1 Pivotal data on mosunetuzumab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, showed high response rates in relapsed or refractory follicular lymphoma (FL)2... Read more
Gavreto is the first and only precision medicine approved in the EU for first-line treatment of people with RET fusion-positive advanced NSCLC Conditional approval is based on results from the phase I/II ARROW study, in which Gavreto led to durable responses in people with RET fusion-positive advanced NSCLC Basel, 19 November 2021 – Roche (SIX:... Read more
Infectious diseases, such as those infections transmitted via respiratory, sexually and transplant, are becoming increasingly difficult to manage and represent an ever-growing medical need for millions of patients worldwide. Access to accurate and reliable diagnostic tests help clinicians improve patient care, limit healthcare spending and contribute to protecting public health. The cobas 5800 System is... Read more
The ranking acknowledges Roche’s commitment to sustainability as an integral part of its business strategy Roche performed particularly well in Operational Eco-Efficiency, Environmental and Social Reporting Basel, 15 November 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) has again been recognised as one of the most sustainable companies in the Pharmaceuticals index of the Dow... Read more
EU marketing authorisation follows approvals in Japan, the United Kingdom and Australia Approval based on data demonstrating Ronapreve reduced risk of hospitalisation in certain patients with mild to moderate disease and reduced risk of symptomatic COVID-19 infections in people exposed to the virus Basel, 12 November 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today... Read more
Recommendation based on data demonstrating Ronapreve reduced risk of hospitalisation in certain patients with mild to moderate disease and reduced risk of symptomatic COVID-19 infections in people exposed to the virus Ronapreve’s combination approach continues to retain neutralisation activity against variants of concern Basel, 11 November 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today... Read more